The new treatment for eczema, specifically chronic hand eczema, currently being assessed for use is delgocitinib, a topical JAK inhibitor.
Delgocitinib: A Potential New Hope for Eczema Sufferers
Delgocitinib offers a promising approach to managing eczema, particularly for those who struggle with persistent hand eczema. Its method of action targets specific pathways involved in inflammation.
How Delgocitinib Works:
- It acts as a JAK inhibitor, reducing inflammation by blocking the Janus kinase enzymes.
- This process helps to reduce skin inflammation that is characteristic of eczema.
Timeline for Availability:
- Delgocitinib is currently undergoing assessment by NICE for potential NHS use.
- If approved, it could become available to patients as early as 2025.
Potential Benefits:
- It may offer a new therapeutic approach, especially for those who have not found relief with current treatments.
- Being a topical treatment, it is directly applied to the affected area.
The Future of Eczema Treatment
The development of delgocitinib reflects ongoing research in finding better and more targeted treatments for eczema. The approval and availability of this new option will likely bring relief to many individuals managing chronic hand eczema.
